Conference abstractPublished 25 Sep 2014

Regulatory requirements and benefits converting to continued process verification

Authors: Magnus Jahnsson

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The new QWP Guideline for Process validation that came into force end-2013 is very similar to the latest FDA guidance. Additionally, the draft annex 15 (qualification and validation) to the EU GMP-guidelines also opens up the possibility to use Continued Process Verification (CPV) instead of traditional process validation. But what are the regulatory requirements that have to be met in order to utilize this option and what are the advantages? What does a company have to do to convert an existing product file into a file that supports CPV and finally what are the major steps that have to be taken in the validation planning to be able to run CPV in a production line? This presentation will answer the questions above in on a high level and drill deeper into the validation planning required.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Longdom does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Developing Drugs
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Magnus Jahnsson”